JP2023524092A5 - - Google Patents

Info

Publication number
JP2023524092A5
JP2023524092A5 JP2022566470A JP2022566470A JP2023524092A5 JP 2023524092 A5 JP2023524092 A5 JP 2023524092A5 JP 2022566470 A JP2022566470 A JP 2022566470A JP 2022566470 A JP2022566470 A JP 2022566470A JP 2023524092 A5 JP2023524092 A5 JP 2023524092A5
Authority
JP
Japan
Prior art keywords
dectin
binder
antibody
seq
chain variable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022566470A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023524092A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2021/030466 external-priority patent/WO2021222894A1/en
Publication of JP2023524092A publication Critical patent/JP2023524092A/ja
Publication of JP2023524092A5 publication Critical patent/JP2023524092A5/ja
Pending legal-status Critical Current

Links

JP2022566470A 2020-05-01 2021-05-03 抗デクチン-2抗体 Pending JP2023524092A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063018952P 2020-05-01 2020-05-01
US63/018,952 2020-05-01
PCT/US2021/030466 WO2021222894A1 (en) 2020-05-01 2021-05-03 Anti-dectin-2 antibodies

Publications (2)

Publication Number Publication Date
JP2023524092A JP2023524092A (ja) 2023-06-08
JP2023524092A5 true JP2023524092A5 (cg-RX-API-DMAC7.html) 2024-05-16

Family

ID=76076494

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022566470A Pending JP2023524092A (ja) 2020-05-01 2021-05-03 抗デクチン-2抗体

Country Status (13)

Country Link
US (3) US11753474B2 (cg-RX-API-DMAC7.html)
EP (1) EP4142881A1 (cg-RX-API-DMAC7.html)
JP (1) JP2023524092A (cg-RX-API-DMAC7.html)
KR (1) KR20230005907A (cg-RX-API-DMAC7.html)
CN (1) CN115461122A (cg-RX-API-DMAC7.html)
AU (1) AU2021262828A1 (cg-RX-API-DMAC7.html)
BR (1) BR112022020639A2 (cg-RX-API-DMAC7.html)
CA (1) CA3175576A1 (cg-RX-API-DMAC7.html)
CL (1) CL2022003012A1 (cg-RX-API-DMAC7.html)
CR (1) CR20220582A (cg-RX-API-DMAC7.html)
IL (1) IL297782A (cg-RX-API-DMAC7.html)
MX (1) MX2022013616A (cg-RX-API-DMAC7.html)
WO (1) WO2021222894A1 (cg-RX-API-DMAC7.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12145993B2 (en) * 2016-06-08 2024-11-19 Shanghai Jiao Tong University School Of Medicine Sequence of antibody heavy chain constant region for enhancing agonistic antibody activity
BR112019000071A2 (pt) 2016-07-07 2019-07-02 Bolt Biotherapeutics Inc conjugados adjuvantes de anticorpo
EP3937984A1 (en) 2019-03-15 2022-01-19 Bolt Biotherapeutics, Inc. Immunoconjugates targeting her2
WO2024216089A1 (en) * 2023-04-13 2024-10-17 Bolt Biotherapeutics, Inc. Anti-dectin-2 antibody combination therapy

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
JP3101690B2 (ja) 1987-03-18 2000-10-23 エス・ビィ・2・インコーポレイテッド 変性抗体の、または変性抗体に関する改良
ATE159548T1 (de) 1990-11-13 1997-11-15 Immunex Corp Bifunktionelle wählbare fusionsgene
AU6953394A (en) 1993-05-21 1994-12-20 Targeted Genetics Corporation Bifunctional selectable fusion genes based on the cytosine deaminase (cd) gene
US5814618A (en) 1993-06-14 1998-09-29 Basf Aktiengesellschaft Methods for regulating gene expression
US5464758A (en) 1993-06-14 1995-11-07 Gossen; Manfred Tight control of gene expression in eucaryotic cells by tetracycline-responsive promoters
US7071171B1 (en) * 1996-12-20 2006-07-04 Board Of Regents The University Of Texas System Unique dendritic cell-associated c-type lectins, dectin-1 and dectin-2 compositions and uses thereof
AU5345901A (en) 2000-04-13 2001-10-30 Univ Rockefeller Enhancement of antibody-mediated immune responses
FR2814642B1 (fr) 2000-10-03 2005-07-01 Ass Pour Le Dev De La Rech En Souris transgenique pour la recombinaison ciblee mediee par la cre-er modifiee
US20070014795A1 (en) 2004-12-30 2007-01-18 Dhodapkar Madhav V Compositions and methods for enhanced dendritic cell maturation and function
AU2006312148B2 (en) 2005-11-07 2012-04-12 The Rockefeller University Reagents, methods and systems for selecting a cytotoxic antibody or variant thereof
CN105837690A (zh) 2006-06-12 2016-08-10 新兴产品开发西雅图有限公司 具有效应功能的单链多价结合蛋白
HRP20210977T1 (hr) 2014-02-10 2021-09-17 Merck Patent Gmbh Ciljano inhibiranje tgf beta
HUE061339T2 (hu) 2014-03-19 2023-06-28 Genzyme Corp Targetáló csoportok helyspecifikus glikotechnikai átalakítása
JP6805142B2 (ja) 2014-11-21 2020-12-23 ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company Cd73に対する抗体およびその使用
WO2017117269A1 (en) * 2015-12-29 2017-07-06 The Board Of Trustees Of The Leland Stanford Junior University Methods and compositions for dectin-2 stimulation and cancer immunotherapy
CN109562153A (zh) 2016-08-07 2019-04-02 诺华股份有限公司 mRNA介导的免疫方法
CA3049791A1 (en) 2017-01-27 2018-08-02 Silverback Therapeutics, Inc. Tumor targeting conjugates and methods of use thereof
JP2020526482A (ja) * 2017-06-28 2020-08-31 ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー デクチン−2刺激及び癌免疫療法のための方法及び組成物
SG11202110663UA (en) 2019-04-05 2021-10-28 Dren Bio Inc Methods of depleting disease causing agents via antibody targeted phagocytosis
EP4225373A4 (en) 2020-10-07 2025-01-08 Dren Bio, Inc. ANTI-DECTIN-1 ANTIBODIES AND METHODS OF USE THEREOF

Similar Documents

Publication Publication Date Title
AU2016226060B2 (en) CD20 binding molecules and uses thereof
JP2025000628A (ja) NKp46結合タンパク質の可変領域
US20200377594A1 (en) Humanized antibodies for cd3
JP2021073224A (ja) 結合分子
JP2022515611A5 (cg-RX-API-DMAC7.html)
JP2020510422A5 (cg-RX-API-DMAC7.html)
CN110325209A (zh) 能够结合cd137和肿瘤抗原的双特异性结合分子及其用途
RU2019140602A (ru) АНТИ-GARP-TGF-β-АНТИТЕЛА
JP2020508334A5 (cg-RX-API-DMAC7.html)
JP2017532037A5 (cg-RX-API-DMAC7.html)
JP2020520665A5 (cg-RX-API-DMAC7.html)
JP2019517539A (ja) 併用療法
JP2022533538A5 (cg-RX-API-DMAC7.html)
CA3120793A1 (en) Anti-cd40 antibody, antigen binding fragment and pharmaceutical use thereof
JP2021513961A (ja) 変異型cd3結合ドメイン、及び疾患の治療のための併用療法におけるその使用
JP2023525695A5 (cg-RX-API-DMAC7.html)
JP2024024114A5 (cg-RX-API-DMAC7.html)
JP2025508882A (ja) 標的化サイトカインおよびその使用方法
EP4154910A1 (en) Binding protein having h2l2 and hcab structures
JP2017521400A (ja) 多重特異的NKp46結合タンパク質
JP2023509373A5 (cg-RX-API-DMAC7.html)
JP2024540148A5 (cg-RX-API-DMAC7.html)
JP2021505637A (ja) 二重特異性cd16結合分子、及び疾患の治療におけるその使用
JP2018529672A5 (cg-RX-API-DMAC7.html)
JP2024533457A5 (cg-RX-API-DMAC7.html)